Price:

BUSINESS

Bakri warns FDA peptide bans fuel $10B gray market

Wednesday, June 3, 2026 · from 3 podcasts
Huberman LabPeter Attia DriveUngovernable Misfits
  • FDA bans push peptides like BPC-157 to risky online sellers sourcing from China.
  • The GLP-1 injection craze normalized self-dosing, lowering the barrier to experimental treatments.
  • Long-term safety for these animal-tested compounds remains almost entirely unknown in humans.

The FDA’s crackdown on compounded peptides hasn't stopped demand - it's rerouted it. Last year, the agency placed BPC-157 and over 20 other peptides on a restrictive list, barring pharmacies from compounding them. The result, according to Dr. Abud Bakri on the Huberman Lab, is a booming $10 billion gray market where consumers buy from 'research only' websites that take Venmo payments.

Almost all the raw materials originate in Chinese labs, leading to a dangerous gamble on purity. Bakri cites cases of mislabeled products, where someone injects a tanning agent believing it's a weight-loss peptide. Without pharmacy oversight, users betting on healing tendons or enhancing longevity become their own test subjects.

"The problem is the data silo. Almost all the foundational evidence comes from a single lab in Croatia. We don't even know the lethal dose for humans because the formal safety trials haven't been done."

- Dr. Abud Bakri, Huberman Lab

Cultural shifts are accelerating the trend. The normalization of GLP-1 drugs like Ozempic has overcome the 'needle ick,' Bakri argues, making self-administration routine. This comfort lowers the threshold for experimenting with unproven peptides for skin or longevity, a pursuit he calls the 'Trinity Stack' protocol popular in elite circles.

The underlying science for many peptides remains thin. BPC-157 shows remarkable tendon repair in rats but its mechanism in humans - possibly acting as an epigenetic modifier - is not fully understood. This regulatory and scientific vacuum creates a paradox where the pursuit of health sovereignty, as emphasized by shows like Ungovernable Misfits, collides with profound biological risk.

Ultimately, the gray market boom reveals a system failure. As demand for performance and longevity outpaces regulatory approval and rigorous science, individuals are left to navigate a high-stakes chemical frontier alone.

#Health#Regulation#Markets
SemaglutideFDA

Source Intelligence

- Deep dive into what was said in the episodes

Huberman Lab
Huberman Lab

Peptides: The Science, Uses & Safety | Dr. Abud Bakri • Jun 1

  • Andrew Huberman frames peptides as FDA-approved drugs like GLP-1 agonists (Ozempic, Mounjaro) and research compounds like BPC-157, which have minimal human studies but long anecdotal use for gut health and tissue repair.
  • Dr. Abud Bakri categorizes peptides scientifically as a language of cell communication, splitting them into those with known receptors (like GLP-1s) and those without (like BPC-157 or TB-500), which changes their clinical effects.
  • Bakri explains BPC-157 is a 15-amino acid fragment of a larger gastric protein discovered in Croatia in the 1990s, inspired by Pavlov’s work on gastric juices and Hans Selye’s stress adaptation theory.
  • Animal studies from one Croatian group show BPC-157 accelerates healing of severed tendons, ACLs, and burn wounds, and protects against gastric ulcers and alcohol withdrawal, but human data is limited to small rectal enema trials for ulcerative colitis.
  • Bakri notes the LD50 for BPC-157 is unknown, complicating FDA approval, and the primary safety concern is its potential to promote angiogenesis (VEGF signaling), which could theoretically fuel tumors, though no such signal exists in animal data.
  • BPC-157’s legal status in the U.S. is ambiguous: it was moved to a 'Category Two' compounding restriction list in late 2024 but removed in April 2025, while state medical boards vary in allowing prescriptions of analogs like pentadecapeptide arginate.
  • Bakri says the active pharmaceutical ingredients for all peptides, including semaglutide and BPC-157, originate in China, with quality varying wildly between pharmaceutical-grade, compounding pharmacy, and gray-market 'research purposes only' sources.
  • Huberman and Bakri agree the GLP-1 craze destigmatized self-injection, fueling a gray-market peptide industry they estimate at $5-10 billion in the U.S. in 2025, with affiliates, including many women, promoting compounds online.
  • Bakri advocates for rigorous human trials on BPC-157, prioritizing ulcerative colitis and GERD for gut protection, addiction and neuropsychiatric effects via the gut-brain axis, and musculoskeletal recovery like post-surgical tendon healing.
  • Huberman describes personal anecdotal results with BPC-157 for a neck injury and pinealon (EDR) for dramatically increasing REM sleep, while Bakri cites Russian research showing pinealon improves cognitive performance, metabolism, and reduces brain fog.
  • Bakri explains pinealon (EDR) is a tripeptide from brain cortex extract that acts as an epigenetic modifier, turning on genes related to brain metabolism and circadian rhythms, with anecdotal side effects of vivid dreams and possible hypoglycemia.
  • Bakri notes epitalon, derived from the pineal gland, is distinct from pinealon and was shown in Soviet research to restore melatonin production in aged animals, potentially countering age-related pineal decline and calcification.
  • Huberman highlights the 'trinity stack' of GLP-1 agonists, growth hormone modulators, and testosterone used by some celebrities and CEOs for rapid fat loss and muscle gain, noting the health outcomes are unknown.
#Health#Longevity#Biology#Regulation
The Peter Attia Drive
The Peter Attia Drive

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements • Jun 1

  • Peter Attia defines four root causes of sleep problems: inadequate sleep pressure, circadian misalignment, hyperarousal, and disrupted sleep architecture. Every behavioral or pharmacological tool acts on one or more of these systems.
  • Attia states 36% of U.S. adults fail to get the recommended seven hours of sleep nightly. Over half report difficulty sleeping, and over 22% meet diagnostic criteria for insomnia.
  • Restless Leg Syndrome afflicts about 3% of adults globally, but a U.S. survey found 13% report a diagnosis. Obstructive sleep apnea likely affects about a third of U.S. adults, with 39% of males and 26% of females impacted.
  • Attia notes a third of U.S. adults suffer from anxiety or mood disorders annually. Of these, 25-45% report severe insomnia, rising to 42-63% for those with comorbid mood and anxiety disorders.
  • Benzodiazepines reduce sleep latency but disrupt sleep architecture, decreasing slow-wave and REM sleep. Despite labels recommending 2-4 weeks of use, meta-analyses show average duration is nearly a decade.
  • Z-drugs account for over 40% of U.S. sleep medication prescriptions, with Ambien making up nearly 90% of that share. They induce anterograde amnesia and carry a black box warning for complex sleep behaviors.
  • Dual Orexin Receptor Antagonists work by dialing down the brain's wakefulness system rather than forcing sedation. A meta-analysis found Duvigo had the most favorable profile of any drug examined, preserving sleep architecture.
  • Animal research led by David Holtzman shows DORAs like Duvigo can reduce interstitial beta-amyloid and pathological tau, unlike Ambien. A small human trial found 20mg of Belsomra decreased CSF amyloid-beta by roughly 20%.
  • Melatonin is a circadian signal, not a sedative. A dose-response meta-analysis found 4mg is optimal for shortening sleep latency, yet many supplements contain vastly inaccurate doses, with content ranging from -80% to +500% of the label.
  • Trazodone increases slow-wave N3 sleep, unlike most sedatives. A 2022 meta-analysis confirmed it increases total sleep time and is popular for off-label use at 50-100mg doses due to its safety and low cost.
  • First-generation antihistamines like Benadryl cause fast tolerance and have significant anticholinergic properties. Observational data links long-term anticholinergic burden to an increased risk of dementia.
  • Evidence for magnesium improving sleep is underwhelming. A trial of magnesium L-threonate, which has better BBB penetration, found no effects on sleep variables in adults aged 50-70 with cognitive impairment.
  • A meta-analysis of five RCTs found Ashwagandha has a small positive effect on sleep, stronger in those with diagnosed insomnia at doses ≥600mg/day for ≥8 weeks. Consumer Lab testing found only 5 of 13 products contained the labeled bioactive amount.
#Longevity#Health#Biology#Brain
Ungovernable Misfits
Ungovernable Misfits

NO HEALTH = NO FREEDOM | FREEDOM TECH FRIDAY 42 • May 31

  • Zach Herbert argues the municipal water supply contains fluoride which lowers population IQ, PFAS forever chemicals, hormonal birth control residues, and other contaminants that require a reverse osmosis system to remove.
  • Herbert installed an under-sink reverse osmosis system with remineralization for about $600. Annual filter replacement costs around $60-70. He warns drinking demineralized RO water can cause dehydration.
  • Herbert recommends Vero Salt for cooking, a microplastic-free salt, and criticizes standard electrolyte packets for containing artificial sweeteners like stevia and citric acid that can damage tooth enamel.
  • He advocates monitoring home CO2 levels with a device like an Aranet monitor, which costs about $189. High indoor CO2 can degrade mental clarity and test performance.
  • Herbert installed a whole-home energy recovery ventilator to maintain outdoor CO2 levels indoors and an electronic air filter superior to HEPA. He warns installing such systems professionally can cost thousands.
  • He replaced home LEDs with incandescent bulbs in bedrooms and high-CRI, no-flicker LEDs elsewhere. Herbert argues cheap LED flicker causes fatigue and their blue-heavy spectrum disrupts circadian rhythm.
  • Herbert used an AI tool to analyze his raw DNA data and discovered three MTHFR mutations, impairing his methylation pathways to 30% of normal function. This explained his low vitamin D levels and led him to take methylated B vitamins.
  • He uses Function Health for biannual blood tests at $365 per year. Testing revealed elevated lead levels, which he reduced by over half through sauna use and blood donation.
  • Herbert recommends privacy-conscious genetic testing as a prerequisite for blood work, suggesting using pseudonyms and Bitcoin payment. He argues understanding genetics first explains why blood markers may be off.
  • He uses tallow-based skincare from Clara and Fritz, NOBS nano-hydroxyapatite toothpaste, and Fountainhead Hair shampoo to avoid artificial chemicals, extending the natural home environment to personal products.
  • Herbert speculates the intense demonization of ivermectin during COVID may relate to its potential anti-parasitic or anti-cancer effects, which authorities might not want the population to discover en masse.
#Health#Longevity#Biology#Digital Sovereignty

Related Stories